Global Hybrid Polymer Market — North America by Polymer Type

Momentive is one of the world's largest producers of silicones and silicone derivatives and, within its parent KCC, forms the core of a vertically integrated silicone platform ranked roughly fourth globally behind Shin-Etsu, Wacker and Dow (Korean sell-side characterisation). Born from GE's 1940s silicone franchise, the company has spent the past decade repositioning from commodity siloxane production toward specialty materials: it exited Leverkusen siloxane production (2016), sold the GE-branded consumer sealants business to Henkel and phased out basic chemicals production at Waterford (2020–2022), and divested its quartz and ceramics business (2020). Its portfolio spans performance additives (silanes, polyurethane additives, coating additives), specialty fluids, elastomers (LSR, HCR), electronic and thermal materials, personal-care ingredients and construction sealants. Under 100% KCC ownership since May 2024 and a new leadership team appointed in 2025–2026, Momentive is pursuing margin recovery after the 2023 silicone downturn, digitisation, and "in-region-for-region" manufacturing, with more than 35% of silicone-segment sales generated in the United States. --- ### Company self-description Momentive describes itself in recent press releases as a premier global advanced-materials company focused on silicone and specialty products, whose technologies are used in agriculture, automotive, aerospace, electronics, personal care, consumer products, and building and construction, and whose stated purpose is enabling "Solutions for a Sustainable World". Its corporate boilerplate (June 2026) identifies it as an indirect wholly owned subsidiary of KCC Corporation and one of the world's largest producers of silicone and silicone derivatives. The Singapore holding entity's registry description adds that the business offers basic siloxane polymers, an additive portfolio including silanes, specialty fluids and urethane additives, and formulated products including elastomers and coatings. ### Independent characterisation | Revenue model element | Estimated role | Basis | |---|---|---| | Product sales (specialty & formulated silicones, additives) | Dominant (~100%) | No other revenue streams disclosed | | Services / technical support | Embedded in product price | Application development centres | | Licensing / royalties | Not publicly disclosed | GE brand used under license for construction sealants | | Subscription | None | — | Momentive is a mid-stream, partially integrated specialty chemicals manufacturer. Upstream, silicone value chains begin with silicon metal, which is converted to methylchlorosilanes (MCS) and then to siloxane intermediates (notably DMC — dimethylcyclosiloxane). Historically Momentive ran MCS/siloxane production in Waterford (NY), Leverkusen (Germany) and Ohta (Japan) plus a China JV; it has progressively shut or reduced Western basic production and now sources intermediates from KCC's integrated Korean operations, other Momentive sites and long-term third-party contracts. Downstream, it formulates and compounds intermediates into thousands of specialty grades sold B2B. **Business model:** almost entirely product sales (B2B, industrial). There is no meaningful subscription or licensing revenue disclosed. Technical service and application development (application centres in the US, UK, Italy, India, Thailand etc.) is bundled into product pricing. Distribution partners (Brenntag in Indonesia, Vietnam, Philippines; TER Chemicals in Europe for personal care) supplement direct sales. **Value-chain position:** Intermediates → specialty formulations. Momentive's competitive advantage lies in formulation know-how, application engineering and a large patent estate, rather than upstream cost leadership (where Chinese integrated producers such as Hoshine, Dongyue and Xingfa have structural advantages). **Customer types:** OEMs and Tier-1 suppliers (automotive, electronics, aerospace), polyurethane foam producers, tyre and rubber compounders (sulphur silanes), coatings/adhesives/sealants formulators, personal-care and cosmetics brands, agrochemical formulators (adjuvants), construction glazing and curtain-wall contractors, medical-device moulders (LSR), and energy/utility equipment makers. **End markets served (company-listed):** agriculture, automotive/transportation (including EV thermal management), aerospace, electronics and semiconductors, data-centre thermal management, personal care and cosmetics, consumer products (including memory-foam mattresses via PU additives), building and construction, healthcare, telecommunications and energy.

Kaneka is a mid-cap Japanese diversified chemical company. Over the past decade it has been reshaping itself from a commodity-heavy vinyls, foams and fibres producer into what management calls a "Life Focus" solutions company. FY2026 sales were a record ¥811.6bn. They are spread across four reportable units: - Material Solutions (PVC, modifiers, MS polymer, the biodegradable polymer Green Planet™) - Quality of Life Solutions (polyimide films, PV, foams, modacrylic fibres) - Health Care Solutions (blood-purification devices, catheters, neuro-coils, pharma CDMO) - Nutrition Solutions (Kaneka Ubiquinol™, probiotics, margarine/yeast/dairy) Kaneka is a global leader in several niche chemistries: MBS/acrylic impact modifiers, silyl-terminated polyether (MS Polymer™), reduced coenzyme Q10, and modacrylic hair fibre. Profitability is structurally low, with a 4.1% operating margin in FY2026 and a 6.4% ROE. The stock traded at a P/B of about 0.7x in September 2026. Management's 2026 plan targets ¥68bn operating income and 10% ROE by FY2029 (Kaneka "FY2028"). It relies on Medical, E&I and supplement growth, plus aggressive capital-efficiency measures. --- ### What Kaneka does Kaneka makes and sells a broad portfolio of chemical, materials, medical, pharmaceutical and food products. It organises them into ten "Solutions Vehicles" (SVs), grouped into four "Solutions Units" (SUs), which are the reportable segments. Per the FY2026 Tanshin segment note, each SU sets a single global strategy and runs Japanese and overseas subsidiaries as one business. **Company's own description (paraphrased from the FY2026 Tanshin segment note):** **Material SU:** supplies high-performance materials for social infrastructure and lighter, more fuel-efficient mobility, plus advanced materials such as biodegradable polymers that serve environmental goals. **Quality of Life SU:** supplies materials and services for energy saving and smart housing and infrastructure, and serves the IoT/AI information economy. **Health Care SU:** combines devices and pharmaceuticals for medicine, health and nursing care. It is building businesses in biopharmaceuticals and regenerative/cell medicine. **Nutrition SU:** supplies distinctive food materials and supplements for diverse diets and health. It also supports agriculture, livestock and fisheries production. **Corporate purpose framing (Three-Year Initiatives 2026).** The corporate purpose is "KANEKA thinks 'Wellness First'". Its supporting pillars are Life Focus Management, Human-Driven Management, R2B+P ("Research to Business + Production") and "Think Global, Act Local". Management defines "life science" broadly. It covers biomanufacturing (Green Planet™, genome editing, fermentation), biopharma, regenerative medicine, supplements, organic dairy, PV and medical devices — all presented as serving "life on Earth". ### Business model and revenue model | Dimension | Characterisation | |---|---| | Revenue type | Almost entirely product sales (B2B materials, devices, ingredients, foods). Contract manufacturing (CDMO) revenue sits within Pharma. Kaneka does not disclose any subscription or licensing revenue line; licensing income is not separately reported | | Product vs. service mix | Not disclosed. Kaneka's independent assessment is that product sales are more than 95% of revenue; services are limited to construction-method/PV installation-related services in QOL and CDMO services in Pharma | | Value-chain position | Mid-stream: intermediates, specialty polymers and additives. Downstream: finished medical devices, PV modules, consumer-facing supplements and dairy products. Upstream exposure through chlor-alkali/PVC (naphtha, salt, power) | | Customer types | Industrial compounders and converters (PVC, adhesives/sealants, automotive), electronics makers (FPC/smartphone, TV), housing builders, hospitals and distributors (medical devices), pharma companies (CDMO/API), supplement brands, food manufacturers and bakeries, agricultural users | | End-markets | Construction and housing; automotive and mobility; electronics/ICT (smartphones, AI-related high-frequency); renewable energy; healthcare (cardiology, nephrology/apheresis, neurovascular, GI endoscopy); pharma; dietary supplements; bakery and food; agriculture | | Geographic mix (FY2026) | Japan 55.2%, Asia 20.1%, Europe 10.3%, North America 9.2%, Other 5.2% (FY2026 Tanshin) | ### "Leading-edge" vs "Foundation" portfolio lens Management splits the portfolio into two groups (Three-Year Initiatives 2026): **Leading-edge businesses:** Modified Silicone polymers (MS), E&I Technology, PV & Energy management, Medical, Pharma, and Supplemental Nutrition. **Foundation businesses:** Vinyls & Chlor-Alkali, Modifiers (MOD), Foam & Residential Techs, Performance Fibers, and Foods & Agris. Leading-edge businesses supplied 53% of operating income in FY2026, up from 48% in FY2025. The target is 56% in FY2027 and 62% by FY2029. The 2026 plan also puts Green Planet™ and genome editing in the life-science growth pool. ### Independent characterisation Kaneka is best understood as a portfolio of ten mid-sized niche businesses sitting on a cyclical commodity base. About 40% of revenue (Material SU) is exposed to Asian PVC pricing and Western construction demand. That base has driven most of the earnings volatility seen in FY2026. The value-creation engine lies elsewhere: **Medical devices:** the Health Care SU earned a 17.9% segment margin in FY2026. **E&I polyimide films:** these benefit from AI-driven high-frequency demand. **Global ubiquinol franchise:** The central investment question is whether these businesses can scale fast enough to lift group margins from about 4% toward the 7.3% FY2029 target. A secondary question is whether that can happen before the corporate cost burden absorbs the gains: unallocated corporate expenses (mainly basic R&D) were ¥39.1bn in FY2026, larger than total group operating income.

Covestro is one of the world's largest producers of high-performance polymer materials and their precursors, built on Bayer's eight-decade legacy in polyurethane and polycarbonate chemistry. It sits in the upstream-to-midstream portion of the chemical value chain, converting petrochemical (and increasingly bio-based and recycled) feedstocks into isocyanates (MDI, TDI, HDI and aliphatic derivatives), polyols, polycarbonate resins and specialty systems for coatings, adhesives, elastomers and films. Roughly half of revenue comes from scale-driven commodity-like "Performance Materials" and half from customer-specific "Solutions & Specialties". After three years of cyclical trough (sales down from €18.0bn in 2022 to €12.9bn in 2025 and net losses each year), Covestro was acquired by ADNOC's international chemicals vehicle XRG in a ~€14.7bn transaction completed in late 2025, giving it a deep-pocketed, feedstock-integrated strategic owner. Its strategic thesis is "Sustainable Future": leadership in circular, climate-neutral polymers, now combined with Gulf-based capacity growth. --- ### What the company does Covestro manufactures polymer materials and components. Its chemistry falls into three technology families: 1. **Polyurethanes (PU)** — isocyanates (MDI for rigid foams, TDI for flexible foams) and polyether polyols, sold to foam makers for insulation (construction, refrigeration/cold chain) and comfort (furniture, mattresses, automotive seating). 2. **Polycarbonates (PC)** — engineering thermoplastic (Makrolon® brand) and compounds/blends (Bayblend®, Makroblend®) for automotive, electrical & electronics, healthcare, lighting and construction glazing. 3. **Coatings, Adhesives & Specialties** — aliphatic isocyanates and derivatives (HDI, IPDI, H12MDI; Desmodur®), polyols/resins (Desmophen®, Bayhydrol®), the former DSM Resins & Functional Materials portfolio (NeoCryl®, NeoRez®, Decovery®), thermoplastic polyurethanes (Desmopan®), elastomers, and specialty films (Makrofol®, Platilon®). ### Business model and revenue model **Product sales ≈ ~100% of revenue:** Covestro does not report material service, subscription or licensing revenue; technology licensing and engineering services are incidental (n/d as a separate line). **Performance Materials:** behaves as a cost-leadership, scale business with prices set by global supply/demand for MDI/TDI/polyols/PC; margins swing sharply with industry utilisation and raw material (benzene, toluene, propylene, chlorine, natural gas, energy) spreads. **Solutions & Specialties:** is a formulation- and application-driven business: tailored grades, technical service, co-development with OEMs, stickier pricing and higher, more stable margins. ### Value-chain position Upstream: buys aromatics (benzene, toluene), propylene, natural gas/energy, chlorine (partly produced in-house via chlor-alkali electrolysis), phenol/acetone/bisphenol A inputs. Midstream: isocyanate, polyol and PC production at large integrated "world-scale" sites (Leverkusen, Dormagen, Krefeld-Uerdingen, Antwerp, Baytown, Shanghai, Tarragona, Map Ta Phut). Downstream: sells mostly B2B to converters (foam producers, compounders, coaters, adhesive formulators) and OEMs. ### Customer types and end-markets Covestro's largest end-markets (historically disclosed shares; latest split n/v) are construction (insulation, floor coatings), automotive & transportation (seating, interiors, lighting, coatings, e-mobility battery housings), furniture & wood processing (mattresses, wood coatings), electrical & electronics (housings, displays), sports & leisure, cosmetics, healthcare (medical-grade PC and TPU), and chemicals/industrial. ### Company self-description (latest annual reporting, paraphrased) Covestro describes itself as one of the world's leading manufacturers of high-quality polymer materials and their components, pursuing a vision of becoming fully circular and supporting customers' sustainability goals ("Sustainable Future" strategy). Every investor release in 2026 closes with: sales €12.9bn in FY2025, 46 production sites, ~17,600 FTE. ### Independent characterisation Covestro is fundamentally a cyclical isocyanates/polycarbonate producer with a growing specialty overlay. Its earnings power is dominated by MDI and PC margins, which collapsed in 2022–2025 due to Chinese capacity additions (notably Wanhua), weak European construction, high German energy costs and soft durable-goods demand. Its strategic differentiators are (a) technology leadership and process efficiency in MDI/TDI/PC, (b) one of the broadest aliphatic isocyanate franchises globally (coatings & adhesives), and (c) an early-mover position in circular feedstocks (chemical recycling of PU foam and PC, bio-attributed MDI/PC). Under XRG ownership, the investment case shifts from public-market equity story to an integrated Gulf-feedstock growth platform, evidenced by the July 2026 MDI expansion program in China and the UAE.

Evonik is Germany's second-largest listed chemicals group after BASF and one of Europe's broadest pure-play specialty chemicals companies, generating €14.1bn of sales and €1.87bn adjusted EBITDA in FY2025. Since April 2025 it has been organised into two operating segments — Custom Solutions (formulated, application-driven specialties for coatings, personal care, pharma, and industrial additives) and Advanced Technologies (scale- and technology-driven platforms in silica, hydrogen peroxide, high-performance polymers, crosslinkers and animal-nutrition amino acids) — plus an Infrastructure segment (SYNEQT site services, Oxeno C4 chemicals) earmarked for divestment. Its competitive identity rests on deep process know-how, integrated German Verbund sites (Marl, Wesseling, Rheinfelden, Essen, Hanau), and leadership positions in global niches (fumed silica, DL-methionine, PA12, pharma excipients/lipids). The investment case is a transformation story — €400m-plus cost reduction, portfolio pruning, deleveraging — now overlaid by a live takeover approach from BASF and a near-majority foundation shareholder whose stance is pivotal. --- ### Company self-description Evonik describes itself as a global chemical company that goes "beyond chemistry" by combining innovative strength with leading technological expertise, providing customers with a competitive advantage through tailor-made products and solutions — positioning itself as a "superforce for industry" (company boilerplate, press releases 2026; Company Factbook 2026). Its stated strategic pillars (Capital Markets Day, 22 May 2025) are: a differentiated portfolio in two segments, sustainable innovation, a balanced regional footprint (ambition of roughly one-third of sales in each of Americas, EMEA and Asia-Pacific), and a performance culture. ### Independent characterisation Evonik is a mid-cap, diversified specialty and "semi-specialty" chemicals manufacturer. Roughly 80% of FY2025 sales (€11.5bn of €14.1bn) came from the two core segments; the remaining ~18–19% came from Infrastructure & Other, which bundles low-margin site services and the cyclical C4 (Oxeno) petrochemical chain. The business is overwhelmingly a product business (manufactured chemicals sold B2B under supply contracts, frame agreements and spot), with smaller service/contract components: (i) pharma CDMO and contract manufacturing (Health Care — lipids/LNPs, drug substances, oral drug delivery), (ii) site infrastructure and utility services sold by SYNEQT to ~two dozen third-party companies in the Marl and Wesseling chemical parks, and (iii) licensing/technology (e.g., HPPO hydrogen peroxide technology with partners; catalysts). Subscription revenue is negligible. Precise revenue-model split (product vs service vs licensing) is n/d. ### Value-chain position Evonik sits mid-stream: it buys petrochemical feedstocks (C4 raffinate, propylene, methanol, ammonia, natural gas/energy, silicon metal, sulphur) and converts them into intermediates and formulated specialties sold to formulators and OEMs. Upstream integration is partial (own C4 cracking downstream of refinery/cracker streams at Marl and Antwerp; own HCN and methionine chain in Antwerp, Mobile and Singapore). Downstream, it rarely sells to consumers; its products are ingredients typically <5% of the customer's cost but critical to performance ("small cost share, high value-in-use"), which supports pricing power in the specialty businesses. ### Customer types and end markets Customers include paint and coatings formulators, adhesives and sealants makers, tyre and rubber producers (silica/silanes), cosmetic and household-care brands, pharmaceutical and biotech companies (excipients, lipids, CDMO), animal-feed mills and integrators (methionine), plastics and automotive suppliers (PA12, PEEK), aerospace (ROHACELL foams), pulp & paper, electronics and semiconductors (high-purity silanes/chlorosilanes, H2O2), renewable energy and hydrogen (membranes, catalysts), and biodiesel producers (alkoxide catalysts). End-market exposure is broad: consumer/personal care, health care, food/feed, automotive and mobility, construction, coatings, industrial, energy/agriculture. A precise end-market % split for FY2025 is n/d in sources reviewed.

Company Headquarters: US Founded: 1887 Workforce: ~ 10,000 Company Working: H.B. Fuller Company (H.B. Fuller) is a pioneer leader who designs, manufactures, and sells sealants, adhesives, and other chemical products, globally. It operates mainly through five business segments, namely, Americas Adhesives, EIMEA, Asia Pacific, construction adhesives, and engineering adhesives. The company offers its products for applications in medical, construction, electronics, energy, transportation, and other industrial sectors. Grouts, sealants, and other related products are offered by the company. Moreover, it offers its products and solutions through various brands, such as Advantra, Clean Melt, EternaBond, and Sesame. H.B. Fuller has its presence in more than 30 countries of the Americas, Europe, the Middle East & Africa, and Asia-Pacific. It has its operation in countries such as the US, the UK, Spain, France, Germany, Czech Republic, Italy, Portugal, Egypt, the UAE, India, and Australia. Ramapo Sales and Marketing, Inc. and Dalton Holdings, LLC, are a few of its subsidiaries.

### Key facts | Item | Detail | |---|---| | Legal name | Wacker Chemie AG | | Former names | Dr. Alexander Wacker Gesellschaft für elektrochemische Industrie (founding entity, 1914); Wacker-Chemie GmbH (GmbH form used for most of the 20th century; converted to AG in 2005 ahead of the IPO) | | Founded | 1914, by Dr. Alexander Wacker. The Burghausen plant began operating during World War I. | | Incorporation jurisdiction | Federal Republic of Germany (Aktiengesellschaft; two-tier board under the German Stock Corporation Act) | | Headquarters | WACKER House, Werksviertel district, Munich. Address on 2026 press releases: Gisela-Stein-Straße 1, 81671 Munich. The previous HQ address, Hanns-Seidel-Platz 4, 81737 Munich, still appears in some third-party directories. | | Stock exchange / tickers | Frankfurt Stock Exchange (Xetra): WCH. Bloomberg: WCH GR. Reuters: WCHG.DE. US OTC (unsponsored): WKCMF | | ISIN / WKN | DE000WCH8881 / WCH888 | | CUSIP | None. There is no SEC registration and no sponsored ADR. | | IPO | 10 April 2006 | | Share capital | EUR 260,763,000, split into 52,152,600 bearer shares. Of these, 49,677,983 are outstanding (excluding treasury) and 2,474,617 are treasury shares (about 4.7%). | | Fiscal year end | 31 December | | Employees (31 Dec) | 2025: 16,467; 2024: 16,637; 2023: 16,378; 2022: 15,725 | | German workforce (2025) | 10,749 employees in Germany; 5,718 abroad | | Auditor | PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft. PwC gave an unqualified opinion on the FY2025 consolidated statements (AR2025, Executive Board declaration). The previous long-standing auditor was KPMG. | | Market capitalisation | EUR 3,445.2M at 31 Dec 2025 (EUR 69.35 per share; AR2025). About EUR 4.34bn at EUR 87.45 on 13 Sep 2026 (derived: 49.68M outstanding shares × price). Some data vendors quote about EUR 4.5–4.7bn using the total share count including treasury shares. | | Credit rating | None published. Wacker states it relies on bank credit lines and promissory notes (Schuldschein) and does not issue rated instruments (AR2025). | | Website | www.wacker.com | | Business divisions | Silicones, Polymers, Biosolutions, Polysilicon | | FY2025 headline figures | Sales EUR 5,485.3M; reported EBITDA EUR 426.7M; EBITDA before special items about EUR 529M; net result EUR -804.9M; no dividend | Wacker Chemie is a Munich-headquartered, family-controlled, integrated chemicals group. Its two root raw materials are metallurgical silicon and ethylene. From these it builds four businesses: **Silicones:** This is about half of group sales and is one of the world's broadest silicone portfolios. **Polymers:** This division is a global leader in vinyl acetate-ethylene (VAE) dispersions and dispersible polymer powders, sold mainly into construction. **Polysilicon:** This division supplies hyperpure semiconductor- and solar-grade silicon from Burghausen, Nünchritz and Charleston (USA). **Biosolutions:** This is a smaller biotech and contract-manufacturing (CDMO) unit spanning fermentation products, cyclodextrins, proteins and mRNA. The group's strengths are process integration in a closed chlorine-silicon loop, deep application know-how and a German-centred asset base. That same German base is now its principal weakness. High energy costs, Chinese overcapacity in silicones and polysilicon, and weak construction demand drove a EUR -805M net loss in FY2025. Management's response is the PACE programme, targeting more than EUR 300M of annual cost savings by 2027. It is paired with a pivot toward specialties, semiconductor-grade polysilicon and biotech. --- ### What the company does Wacker converts two feedstock chains into intermediate and specialty materials sold business-to-business. 1. **The silicon chain.** Metallurgical silicon is converted into chlorosilanes, then into siloxanes and silicones, pyrogenic (fumed) silica, and hyperpure polysilicon. 2. **The ethylene chain.** Ethylene and acetic acid are converted into vinyl acetate monomer (VAM), then into VAE dispersions, dispersible polymer powders, and solid resins. The defining feature is integration. By-products of one step are feedstocks for another, especially in the silicon/chlorine and hydrogen-chloride loops at Burghausen and Nünchritz. This supports cost position and resource efficiency, but it also creates high fixed costs and utilisation sensitivity. Management repeatedly cites low plant utilisation as a FY2025 earnings drag (FY2025 press release). ### The company's own description (paraphrased from AR2025 and releases) Wacker describes itself as a globally active chemical company with four business divisions. It develops and manufactures products, intermediates and technologies for virtually all key industries. It positions its chemical divisions on specialties, its polysilicon division on the semiconductor market, and Biosolutions on biotech solutions. This three-part strategic focus was articulated by CEO Christian Hartel at the FY2025 annual press conference (11 Mar 2026). ### Independent characterisation Wacker is best understood as a cyclical, energy-intensive, process-integrated materials company carrying a growing specialty overlay. Commodity exposure remains material in three places: - standard silicones (siloxanes and fluids); - solar-grade polysilicon; - part of the VAE and powders business. These are precisely where Chinese capacity additions have destroyed pricing. The specialty overlay is real but not yet dominant. Examples include: - liquid silicone rubber (LSR); - medical-grade and electronics silicones; - silane-terminated polymers; - semiconductor-grade polysilicon; - biologics CDMO. The FY2022 peak (EBITDA EUR 2.08bn, 25.4% margin) and the FY2025 trough (reported EBITDA EUR 427M, 7.8% margin) show an earnings amplitude typical of commodity chemicals rather than specialty peers. ### Revenue model | Revenue type | Approximate share | Description | |---|---|---| | Product sales (chemicals and materials) | About 97% (derived: everything except Biosolutions' service component) | Spot and contract sales of silicones, polymers and polysilicon. Polysilicon historically relied on multi-year supply agreements with prepayments, especially for solar. | | Contract manufacturing services (CDMO) | Part of Biosolutions (division sales EUR 360.4M in FY2025, 6.6% of group); service share not separately disclosed | Fee-for-service development and GMP manufacture of biologics, mRNA, plasmid DNA and live biotherapeutics via Wacker Biotech (Jena, Halle, Amsterdam, León, San Diego) | | Licensing / subscription | Not material; not separately disclosed | Some process-technology know-how, not reported as a revenue line | | "Other" segment | EUR 142.2M in FY2025 (2.6%) | Infrastructure and site services, corporate items | ### Value-chain position **Upstream:** Wacker produces part of its own silicon metal at Holla, Norway. It buys the remainder, plus ethylene, methanol, acetic acid and energy (electricity and gas), largely in Germany. **Midstream (core):** Chlorosilanes, siloxanes, VAM and polysilicon. **Downstream:** Formulated specialty products sold to OEMs and formulators. Wacker does not generally sell to end consumers. ### Customer types and end-markets | End-market | Primary divisions | Key applications | |---|---|---| | Construction | Polymers, Silicones | Tile adhesives, self-levelling compounds, external insulation (ETICS), sealants, masonry protection, paints | | Automotive and transportation | Silicones | Gaskets, cables, EV battery thermal management, LSR parts | | Electrical and electronics | Silicones, Polysilicon | Encapsulants, potting compounds, high-voltage insulators, semiconductor wafers (via the Siltronic and other wafer customers) | | Semiconductors | Polysilicon | Hyperpure polysilicon for Czochralski (CZ) and float-zone (FZ) crystal pulling | | Solar / photovoltaics | Polysilicon | Solar-grade polysilicon | | Personal care and consumer goods | Silicones, Biosolutions | Emollients, hair-care silicones, cyclodextrins | | Textiles, paper, coatings | Silicones, Polymers | Release coatings, softeners, binders | | Medical and healthcare | Silicones, Biosolutions | Medical-grade silicones, pharmaceutical proteins, mRNA, vaccines | | Food and agriculture | Biosolutions, Polymers | Cysteine, gum-base resins (polyvinyl acetate), nutraceutical actives |

AGC is a Tokyo-based materials group that grew out of Japan's first flat-glass producer into a five-segment portfolio spanning architectural glass, automotive glass, electronics, chemicals and life science. It reported FY2025 net sales of JPY 2,058.8 billion and operating profit of JPY 127.5 billion. Management runs an "ambidextrous" model: mature, asset-heavy core businesses (float glass, automotive glazing, display substrates, chlor-alkali) are expected to generate cash, while four strategic businesses (mobility, electronics materials, performance chemicals and life science CDMO) are expected to deliver growth. The company claims leading global shares in automotive glass, ETFE fluoropolymer and car-mounted cover glass, and number-two positions in TFT glass substrates and EUV mask blanks. Its problem is returns. ROE has been below 5% in each of the last four years after impairments of roughly JPY 125 billion in display (2022) and in biopharmaceutical CDMO (2024), and the stock trades at about 0.67 times book. The current agenda is ROCE repair, lower capital expenditure and a semiconductor-materials build-out. --- **What the company does.** AGC manufactures and sells glass, electronic materials, chemicals and ceramics, and provides contract development and manufacturing (CDMO) services for pharmaceuticals and agrochemicals. Glass remains the largest activity: the group operates 26 float lines worldwide (two through an equity affiliate) and automotive glass plants on five continents. The Chemicals segment is the largest single reporting segment by revenue (28% of FY2025 sales) and the second-largest profit contributor after... more precisely, it was the largest profit contributor in FY2025 at JPY 53.0 billion, ahead of Electronics at JPY 47.5 billion (Financial Review 2025). **The company's own description.** AGC frames its mission as being "an everyday essential part of our world" through unique materials and solutions (Group Philosophy "Look Beyond", revised January 2025; Financial Review 2025). Since 2016 it has divided the portfolio into core businesses and strategic businesses, and in 2021 it adopted the long-term strategy Vision 2030, which targets a portfolio that is resilient to market swings and high in asset efficiency, growth and carbon efficiency. **Independent characterisation.** AGC is best understood as three different economic engines under one balance sheet: 1. **Cyclical, capital-intensive commodity businesses.** Float glass in Europe, Asia and Brazil, and chlor-alkali/PVC in Southeast Asia. Earnings follow construction activity, energy costs, and caustic soda and PVC spreads. These businesses hold a large share of operating assets and currently earn sub-10% ROCE. 2. **Engineered-product businesses tied to OEM cycles.** Automotive glass and display glass substrates. Both went through heavy restructuring between 2020 and 2025; Automotive reached ROCE above 10% before common-cost allocation in FY2025, and Display is targeted to reach 10% in 2027. 3. **Differentiated materials and services.** Semiconductor materials (EUV mask blanks, CMP slurry, synthetic quartz, SiC parts), optoelectronics, fluorochemicals, and CDMO. These earn the group's highest returns (Electronics and Integrated Chemicals) and its worst (Life Science, loss-making since FY2023). **Revenue model.** Almost all revenue is product sales to industrial customers. The service element is the CDMO business (Life Science, 6.5% of FY2025 sales), which earns fees for process development and batch manufacturing under project and multi-year contracts. Licensing and subscription revenue are not separately disclosed and are immaterial. The split between product and service revenue is not publicly disclosed beyond the segment figures. **Value-chain position.** AGC is an upstream and midstream materials supplier. It melts and forms glass, runs salt electrolysis and fluorine chemistry from raw salt and fluorite, and sells into fabricators, tier-one suppliers, OEMs, panel makers, chipmakers and pharmaceutical companies. In architectural glass it also has downstream processing and distribution in Japan and Europe. **Customer types and end markets.** Construction and renovation (window glass, Low-E, PVC), automotive OEMs and replacement glass distributors, display panel makers, semiconductor device and equipment makers, smartphone camera supply chains, chemical, pulp, alumina and nickel refiners (caustic soda), and pharmaceutical, biotech and agrochemical companies. Customer concentration figures are not publicly disclosed. Sources: Financial Review 2025; AGC Data Book; FY2025 results presentation (6 Feb 2026).